Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a clinical-stage precision medicine company with a strong pipeline of medicine candidates in precision oncology and genetic disease. The company utilizes its Dynamo platform, which integrates computational and experimental approaches, to target previously intractable or inadequately addressed drug-protein targets. The recent positive top-line data for zovegalisib, with a 60% volumetric response rate and excellent tolerability, positions the company to potentially challenge existing treatments and expand into new patient populations. With a solid financial position and potential for significant growth, there is optimism for Relay Therapeutics' stock and its ability to bring life-changing therapies to patients.

Bears say

Relay Therapeutics is a clinical-stage precision medicine company with a pipeline of potential therapies for precision oncology and genetic diseases. However, despite positive feedback from ISSVA suggesting that their drug zovegalisib is an improvement over other treatments, including potential accelerated approval in a large market, there are still concerns about potential side effects and mixed results in clinical data. Additionally, the company may face financial risks in the future as they seek additional funding for drug development, which could create dilution risk for existing shareholders.

RLAY has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 9 analysts, RLAY has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.